How Neutrophil Counts Are Followed as Neutropenia Recovers and When Precautions Ease

The printout comes back in a plain envelope, and the first thing most people do is hunt for one line. Not hemoglobin, not platelets. The neutrophils. After weeks of taking your temperature twice a day and turning down a friend’s dinner invitation, that single figure feels like a verdict on how much of ordinary life you are allowed to have back.

Following neutropenia recovery blood counts is less like reading a verdict and more like watching a tide come in. The number matters, but so does the direction, the speed, and how many days it has been heading the right way. A team looking at the same sheet is asking a different question from the one the patient asks: not “is it normal yet?” but “is the marrow reliably back at work?”

This explainer walks through what the count measures, why it falls, how recovery typically unfolds, and how clinicians decide when the extra caution can be loosened. Every threshold here is a general one; the timing for any individual sits with the treating team.

What neutropenia recovery blood counts actually tell you

Neutropenia means having too few neutrophils, the white blood cells that act as the body’s first responders against bacteria and fungi. Neutrophils make up the largest share of white cells, roughly 40 to 60 percent in a healthy adult according to MedlinePlus, and they arrive at a wound or an infected tooth within hours. When their numbers drop, the immune system loses its front line before anything else.

The figure everyone watches is the absolute neutrophil count, or ANC. A laboratory reports white cells in two ways: as a total and as a differential, which splits that total into cell types. The ANC is the total white count multiplied by the percentage of neutrophils, and it is expressed as cells per microliter of blood. A microliter is about a fiftieth of a raindrop, which puts the number in perspective.

Neutropenia recovery blood counts, then, are simply repeated ANC results plotted over time. A single result is a snapshot. Two results a few days apart show direction. Three or more start to show the shape of the curve, and that shape is what tells a hematologist whether the bone marrow has genuinely restarted production or is merely sputtering.

There is one more layer worth understanding. Neutrophils survive in the bloodstream only briefly, on the order of a day, before they leave to patrol tissues or are retired. The count you see is not a stockpile. It is a measure of how fast the marrow is currently shipping new cells. That is why a rising count is such reassuring news: it means the factory floor is moving again, not that a warehouse has been found.

Neutrophil count normal range and how neutropenia is graded

Most laboratories treat an ANC of about 1,500 cells per microliter or higher as the lower edge of the normal neutrophil count range for adults, and Mayo Clinic defines neutropenia as a count below that level. The upper limit of normal is often quoted near 7,000 to 8,000, but the upper end rarely matters in a recovery discussion. What matters is how far below 1,500 the count has fallen, because infection risk rises steeply rather than gradually.

Clinicians divide the low range into grades. The categories below follow Cleveland Clinic’s patient information, with the lowest tier taken from the Infectious Diseases Society of America guideline on fever in neutropenic patients.

ANC (cells per microliter)	Usual label	What it generally means for infection risk
1,500 or above	Normal range	Typical defenses against bacterial infection
1,000–1,500	Mild neutropenia	Slightly increased risk; many everyday activities continue
500–1,000	Moderate neutropenia	Meaningfully higher risk; closer monitoring
Below 500	Severe neutropenia	High risk; fever is treated as an emergency
Below 100	Profound neutropenia	Highest risk; infections may spread quickly

Two caveats keep this table honest. First, healthy people of African, Middle Eastern and some other ancestries commonly run baseline counts below 1,500 without any added infection risk, a pattern often called benign ethnic neutropenia. Their “normal” is lower, and their recovery target should be judged against their own baseline. Second, the grades describe risk in populations. A person at 900 who is climbing fast may be in a better position than a person at 1,100 who has been stuck for a week. The number frames the conversation; it does not end it.

Why neutrophil counts fall in the first place

The bone marrow is a remarkably busy organ. It produces billions of neutrophils every day to replace cells that live only briefly, which makes it exquisitely sensitive to anything that interrupts rapidly dividing cells. That sensitivity is the whole story behind most neutropenia.

Chemotherapy is the most common cause seen in hospital practice. Many chemotherapy classes work by damaging cells that are copying their DNA, and the neutrophil precursors in the marrow are doing exactly that. The mature neutrophils already in circulation are largely spared, which is why the count does not crash the day after an infusion. It falls over the following one to two weeks as the existing cells are used up and the pipeline behind them has emptied.

Other causes follow different patterns. Radiation to large areas of marrow-rich bone can have a similar effect. Some medicines outside oncology, including certain antibiotics, antithyroid drugs and antipsychotic agents, can trigger an immune reaction against neutrophils or suppress production directly; this is usually reversible once the medicine is stopped under supervision. Viral infections such as influenza can temporarily push counts down. Autoimmune conditions, some nutritional deficiencies, an enlarged spleen, and primary marrow disorders such as leukemia or aplastic anemia can all reduce the count, each with its own recovery trajectory.

Understanding the cause changes how recovery is followed. After a defined chemotherapy cycle the team expects a predictable dip and rebound, so the schedule of blood draws is planned around it. After a drug reaction, recovery is watched from the day the medicine stops. In a chronic marrow disorder, “recovery” may mean stabilizing at a lower plateau rather than returning to a textbook value. Same test, very different questions.

What actually happens when your blood count is checked

The test itself is unglamorous. A small tube of blood is drawn from a vein in the arm or, for people with a central line or port, taken from that device. The sample goes to an analyzer that counts cells by size and by how they scatter light or conduct electricity. The whole run takes minutes, and most hospital laboratories can report a complete blood count with differential within an hour or two of receiving it.

A complete blood count, usually shortened to CBC, measures red cells, white cells and platelets together. The differential is the extra step that breaks the white cells into neutrophils, lymphocytes, monocytes, eosinophils and basophils. When counts are very low, the analyzer may flag the sample and a technologist will look at a stained smear under a microscope to confirm the numbers and to check for immature forms.

Those immature forms deserve a mention. As the marrow restarts, it often releases neutrophils a little early, and these younger cells, sometimes called bands or left-shifted cells, appear in the blood before the count itself has climbed much. Some laboratories also report an immature granulocyte percentage. Seeing these cells is frequently the first laboratory sign that recovery has begun, sometimes a day or two before the ANC moves.

Timing of the draw is mostly practical. Neutrophil counts vary slightly across the day and rise after exercise, a large meal or stress, so teams try to draw at a consistent time when they are tracking a trend. Recent steroid medicine can raise the count without meaning the marrow has recovered, because steroids push neutrophils off blood vessel walls into circulation. Your team will factor that in; you do not need to, but it explains why a result is occasionally read with a raised eyebrow.

How long does neutropenia last after chemotherapy?

For most standard chemotherapy regimens given in cycles, the count reaches its lowest point, called the nadir, roughly 7 to 14 days after the infusion, and Cleveland Clinic describes recovery toward the normal range over the following one to two weeks, so that many people are back near baseline by three to four weeks. That is why so many regimens run on a 21-day or 28-day cycle: the schedule is built around giving the marrow time to recover before the next dose.

The phrase “most people” is doing real work in that sentence. Several factors stretch or compress the timeline, and the treating team weighs them for each person:

• Intensity of the regimen: higher-intensity or multi-drug regimens produce deeper and longer nadirs than single-agent or lower-intensity treatment.
• Prior treatment: marrow that has been through several cycles, or through earlier radiation, tends to recover more slowly with each round.
• Age and general health: older adults and people with kidney or liver impairment, or poor nutrition, often take longer.
• Marrow involvement: when a cancer itself occupies marrow space, recovery can be delayed until the disease responds.
• Growth factor support: medicines that stimulate neutrophil production can shorten the neutropenic window by several days.

Treatments for leukemia and stem cell transplantation are a different category altogether. There the goal is deliberately to clear the marrow, so the ANC may sit below 500 for two weeks or longer, and recovery is measured against engraftment, the point at which the new marrow begins producing cells. Those patients are usually monitored in or near hospital throughout, with counts checked daily.

None of these ranges is a promise. They are patterns drawn from large groups, and the only timeline that applies to you is the one your own counts draw.

What the following days and weeks usually look like

Picture a typical three-week cycle from the patient’s side of the table. In the first few days after treatment the count is often normal or even a touch high, and it is tempting to feel that the warnings were overstated. This is the calm before the dip, because the cells already in circulation have not yet been used up.

Somewhere in the second week the count falls. Teams commonly schedule a blood draw around the expected nadir, partly to know how low it went and partly because that is the window when fever needs the fastest response. Many people feel more tired in this stretch, though fatigue is a poor guide to the count; plenty of people feel fine at an ANC of 300 and exhausted at 3,000.

Toward the end of the second week or into the third, the first signs of recovery appear. The smear shows young neutrophils. The ANC ticks up from, say, 400 to 700. Two or three days later it may be past 1,000. The climb is often faster than the fall, because a recovering marrow tends to overshoot slightly, sometimes pushing the count briefly above the person’s usual baseline before it settles.

How often blood is drawn depends on where you are on that curve. During the nadir, checks may be every few days, or daily if you are in hospital. Once the count is clearly rising, the interval usually stretches to weekly, then to a single check before the next cycle. If growth factor support is being used, teams sometimes wait a few days after the last injection before drawing, because counts measured while the medicine is active can overstate the marrow’s own output.

The pattern repeats each cycle, with the team comparing this cycle’s curve with the last one. A nadir that is deeper or later than before, or a recovery that is slower, is one of the main reasons a subsequent dose might be adjusted or delayed. That decision always rests with the prescribing clinician.

Who is followed most closely, and who is asked to wait

Not everyone with a low count is monitored the same way, and not everyone gets the all-clear at the same threshold. Two people can hand in identical results and leave with different instructions, because the count is only one input.

Closer monitoring, with more frequent draws and a lower bar for hospital review, is usually applied when the expected nadir is deep or prolonged, when someone has had a previous episode of fever during neutropenia, when there is a central line or other device that could harbor infection, when mucositis (inflammation of the mouth and gut lining) has broken the body’s barrier defenses, or when age, frailty or conditions such as diabetes or chronic lung disease add risk. The Infectious Diseases Society of America guideline explicitly separates high-risk from low-risk patients, with the anticipated duration and depth of neutropenia as the central factor.

People with benign ethnic neutropenia or a long-standing stable low count are a contrasting group. Their counts may never reach 1,500, yet their infection history is unremarkable, and treating their baseline as a problem would lead to needless anxiety and delayed treatment. For them, recovery is judged against their own usual level.

Who is asked to wait longer before precautions ease? Typically those whose count is rising but not yet stable, those who have recently had an infection that is still being treated, those on continuous therapies that will keep suppressing the marrow, and anyone whose next cycle is due within days, since another dip is imminent. Transplant recipients often keep precautions for weeks after the ANC recovers, because other parts of the immune system, particularly lymphocytes, lag well behind neutrophils.

Waiting is not a judgment on how well you are doing. It reflects the simple fact that neutrophils are the fastest cell to recover and not the only one that matters.

How growth factor medicines change the recovery curve

Many people going through cyclical chemotherapy are offered a class of medicines called granulocyte colony-stimulating factors, or G-CSFs. Filgrastim and pegfilgrastim are the generic names most often encountered. They are not chemotherapy and they do not treat the cancer. They are laboratory-made versions of a signaling protein the body already produces, and their job is to tell the marrow to make and release neutrophils faster.

Mechanically, G-CSF acts on neutrophil precursors at several stages: it speeds their division, shortens the time they spend maturing, and encourages the marrow to release finished cells into the blood sooner. The net effect, described in NHS and Cleveland Clinic patient information, is a shallower and shorter nadir. The count still falls, but it usually does not fall as far or stay down as long, which reduces the window in which a fever would be dangerous.

Two consequences matter for anyone reading their own results. First, a count drawn while G-CSF is active may be higher than the marrow’s unassisted output, and it often includes many immature forms. Teams know this and may time draws accordingly. Second, bone or back ache during the days the medicine is working is common and reflects marrow activity; it is worth mentioning to the team, and it is not a sign that something has gone wrong.

Whether growth factor support is used, in which cycles, and in what form is a decision for the prescribing clinician, based on the regimen’s known risk of febrile neutropenia and the individual’s risk factors. It is not something to start, stop or adjust on your own, and nothing in this article should be read as a recommendation either way.

Neutropenic precautions: what they involve and when they usually ease

The term “neutropenic precautions” covers a set of habits designed to reduce exposure to bacteria and fungi while the body’s first line of defense is thin. The core of them is unremarkable and, honestly, good hygiene for anyone: frequent hand washing, keeping the mouth clean with a soft brush, caring for any line or wound exactly as taught, and avoiding people with obvious infections. Layered on top are measures that make sense only while the count is low: checking temperature regularly, avoiding crowded indoor spaces, steering clear of gardening and litter boxes, and cooking meat, eggs and fish thoroughly.

Which precautions ease first, and at what count, varies between institutions, and this is an area where the evidence is thinner than patients might expect. The CDC’s guidance for people receiving chemotherapy emphasizes hand hygiene, food safety and prompt attention to fever as the measures with the strongest support. The so-called neutropenic diet, which historically banned raw fruit and vegetables, has not been shown in randomized trials to reduce infections compared with ordinary safe food handling, and many centers have relaxed it accordingly. If your team still advises it, follow their guidance; if they do not, that is consistent with current evidence, not carelessness.

In practice, most teams begin loosening the social and activity restrictions once the ANC is above 1,000 and clearly rising, and they lift most remaining precautions when it passes 1,500 or returns to the person’s known baseline, usually confirmed on more than one draw. Fever vigilance tends to be the last thing to go, precisely because it is cheap and the consequence of missing a fever is large.

The decision is never made by a threshold alone. Your team will weigh the trend, the timing of the next cycle, any lines or wounds, and how the rest of the blood count looks. Ask them to tell you explicitly which precautions still apply and which have ended, so you are not carrying restrictions you no longer need.

Why the trend in neutropenia recovery blood counts matters more than one number

A hematologist reading a series of counts is doing something closer to weather forecasting than to grading an exam. The isolated value is the least informative part. Consider two people, each with an ANC of 800 today. The first was at 300 two days ago; the second was at 1,400 a week ago and has been drifting down. Same number, opposite situations. The first is likely to be above 1,500 within days. The second may be heading into a nadir, or may have a new problem suppressing the marrow.

Three features of the curve carry most of the meaning in neutropenia recovery blood counts:

• Direction: is the count rising on consecutive draws, or bouncing around a flat line?
• Slope: a recovering marrow typically produces a brisk rise, often doubling within a couple of days; a slow crawl can suggest ongoing suppression or a limited reserve.
• Composition: are immature forms appearing, a sign of active production, or is the rise made up of mature cells released by a steroid dose or by stress, which does not indicate recovery?

The other cell lines add context. Platelets often lag a few days behind neutrophils in recovery, so a rising ANC with platelets still falling is not alarming. Hemoglobin recovers slowest of all because red cells live for months and the marrow prioritizes the cells that turn over fastest. When all three lines are stuck, the question shifts from “when will it recover” to “what else is going on”, and the team may look for infection, medicine effects, nutritional deficiency or marrow involvement.

This is why the answer to “is my count good?” is so often “let’s see the next one.” It is not evasion. It is the honest shape of the information.

ANC recovery after chemotherapy and the timing of the next cycle

Before each new cycle of chemotherapy, a blood count is drawn, and the ANC on that day is one of the main gatekeepers. Most regimens specify a minimum neutrophil count, often somewhere between 1,000 and 1,500, and a minimum platelet count, before the next dose is given. The exact figures are written into each treatment protocol, and they differ between regimens because the drugs differ in how hard they hit the marrow.

When the count falls short, the usual response is a delay of a few days to a week, followed by a repeat draw. NHS chemotherapy information describes this as a routine part of treatment rather than a setback; a short delay to let the marrow catch up is common and is planned for in most schedules. If delays keep recurring, or if a nadir was complicated by fever or a hospital admission, the prescribing clinician may consider a dose reduction or the addition of growth factor support for subsequent cycles. Those are individualized decisions and always sit with the oncology team.

Patients frequently ask whether a delay compromises the treatment. The honest answer is that protocols are designed with modest delays in mind, and that giving chemotherapy into an unrecovered marrow carries a real risk of a deeper, longer, more dangerous nadir next time. The team is balancing dose intensity against safety, and the count is the instrument that lets them do it.

A practical tip: ask your team what minimum ANC your particular protocol requires. Knowing the target turns an anxious wait into an informed one, and it helps you understand why a count that looks “almost normal” to you may still be short of the line for that specific regimen. It also helps you spot, cycle by cycle, whether your marrow is recovering at the same pace, which is exactly the information your team is tracking.

What people often get wrong about neutropenia recovery

Misunderstandings cluster around a few themes, and correcting them lowers anxiety more reliably than any reassurance.

“I feel fine, so my count must be up.” Neutropenia by itself produces no symptoms. Fatigue tracks anemia and the treatment far more than the neutrophil count, and people with an ANC under 100 can feel entirely well right up until a fever starts. The blood test exists precisely because feeling is not a measure.

“A fever is just a fever.” In someone with a normal count, a temperature of 100.4 °F (38 °C) is usually a wait-and-see matter. During neutropenia the same reading is treated as a medical emergency, because the usual signs of infection, pus and redness among them, depend on neutrophils and may never appear. This is the single most consequential difference between neutropenic and ordinary life.

“Once the number hits normal, the risk is gone.” Neutrophils are the first line, not the whole defense. After intensive treatment, lymphocyte recovery and antibody responses can lag by weeks or months, which is why some precautions, and vaccination timing, are handled separately from the ANC.

“Eating better or taking a supplement will raise my count faster.” Good nutrition supports recovery in a general sense, and correcting a documented deficiency of vitamin B12, folate or copper can matter when one is present. No food or over-the-counter supplement has been shown in controlled trials to accelerate marrow recovery after chemotherapy, and some herbal products interact with treatment. Discuss anything you plan to take with your team.

“The neutropenic diet is essential.” As noted earlier, randomized studies have not shown that strict raw-food avoidance reduces infections beyond what standard food safety achieves. Follow your team’s current advice, which may be more relaxed than what a relative was told years ago.

“Antibiotics will fix a low count.” Antibiotics treat infections; they do nothing for the marrow. Some, in fact, can lower counts further.

Questions to ask your care team

Bringing a short list to appointments changes the dynamic. You leave with specifics instead of general reassurance, and the team learns what you are actually worried about. These are the questions that tend to produce the most useful answers during recovery from neutropenia.

• What was my ANC today, and what was it at the last draw? Is the trend what you expected for this point in the cycle?
• What is the lowest my count is likely to go with this regimen, and when do you expect the nadir?
• What minimum ANC does my protocol require before the next cycle, and what happens if I am below it on the day?
• Which precautions still apply to me right now, and at what point, or what count, will each of them end?
• Do you consider me low risk or high risk for complications during neutropenia, and what makes that call?
• Exactly what temperature should prompt me to call, at any hour, and which number do I call? Do you want me to take my temperature on a schedule?
• If I develop a fever, should I come straight to the emergency department, and is there a card or letter I should carry that explains my situation?
• Am I receiving, or being considered for, a growth factor medicine? If so, what should I expect to feel, and how does it affect how you read my counts?
• Are any of my other medicines, including over-the-counter ones, likely to affect my neutrophil count?
• Will you also be tracking my platelets and hemoglobin, and how do those fit into decisions about precautions and the next cycle?
• Once my count recovers, are there vaccines I should schedule, and when?

Write the answers down or ask for them in a summary. Counts, thresholds and phone numbers are exactly the kind of detail that evaporates on the drive home, and having them in your own hand is part of being safely, rather than anxiously, watchful.

When to call your doctor

During neutropenia, and for a stretch after the count begins to recover, the rule is simple: when in doubt, call, and do not wait for morning. The Infectious Diseases Society of America guideline defines fever in a neutropenic patient as a single oral temperature of 38.3 °C (about 101 °F) or a temperature of 38.0 °C (100.4 °F) sustained for an hour, and many teams ask patients to call at the lower figure without waiting the hour. Fever in this setting is treated as an emergency because infection can spread within hours when neutrophils are absent, and because the usual warning signs may be muted or missing.

Seek urgent care, using the number your team gave you or the emergency department, for any of the following:

• Temperature at or above the threshold your team specified, even if you feel well
• Chills, shaking or sweats, with or without a measured fever
• Feeling suddenly unwell, faint, confused or unusually drowsy
• Rapid breathing, breathlessness or chest pain
• New redness, swelling, warmth or pain around a central line, port, wound or injection site
• Sore throat, mouth ulcers or pain on swallowing that is worsening
• Burning on passing urine, or new diarrhea, especially if it persists
• Any new rash, particularly one that spreads quickly
• Uncontrolled bleeding or extensive bruising, which can signal low platelets alongside low neutrophils

Do not take fever-reducing medicines to see whether the temperature comes down before calling; they can mask the one sign that matters. Do not wait for a scheduled blood draw. Tell whoever answers, in the first sentence, that you are receiving chemotherapy or have a known low neutrophil count, so that assessment is fast-tracked.

For non-urgent concerns such as persistent tiredness, mild mouth soreness or questions about which precautions still apply, call during clinic hours. Your team would far rather hear from you about something small than learn afterward that you hesitated over something large. Every decision about tests, treatment and easing precautions remains with them.

Frequently asked questions

How long does neutropenia last after a typical chemotherapy cycle?

For most standard cyclical regimens, the neutrophil count reaches its lowest point roughly 7 to 14 days after treatment and climbs back toward the normal range over the following one to two weeks. Intensive regimens, leukemia treatment and stem cell transplantation produce much longer periods below 500. Your own pattern, tracked cycle by cycle, is the only timeline that truly applies to you.

What is the neutrophil count normal range for adults?

Most laboratories consider roughly 1,500 to 8,000 neutrophils per microliter of blood the adult normal range, and Mayo Clinic defines neutropenia as a count below 1,500. Some healthy people, particularly of African or Middle Eastern ancestry, have a naturally lower baseline without added infection risk. Reference ranges also vary slightly between laboratories, so compare results from the same lab where possible.

What does ANC recovery after chemotherapy look like on a blood test?

Recovery usually shows first as immature neutrophils on the smear, followed by a brisk rise in the absolute neutrophil count over a few days, often doubling between draws. Platelets tend to follow a few days later and hemoglobin recovers slowest. A count that is rising steadily on consecutive draws tells the team the marrow is producing again, which matters more than any single value.

When do neutropenic precautions usually stop?

Most teams begin easing social and activity restrictions once the absolute neutrophil count is above 1,000 and clearly rising, and lift most remaining precautions at 1,500 or your usual baseline, often confirmed on more than one draw. Fever vigilance is typically kept longest. The exact thresholds and timing are set by your treating team, who also consider lines, wounds and the date of your next cycle.

Why is my count normal a few days after chemotherapy if the drug lowers it?

Chemotherapy mainly damages the neutrophil precursors dividing in the bone marrow, not the mature cells already circulating. Those mature cells keep working for a while, so the count looks normal at first. It falls over the next one to two weeks as those cells are used up and the emptied pipeline behind them has not yet refilled. The early normal result is expected, not a sign the treatment missed.

Can I do anything to raise my neutrophil count faster?

No food or over-the-counter supplement has been shown in controlled trials to speed marrow recovery after chemotherapy. Correcting a documented deficiency, such as low vitamin B12 or folate, matters when it exists, and good general nutrition supports recovery broadly. Growth factor medicines can shorten the neutropenic window, but whether they are appropriate is a decision for your prescribing clinician, not something to seek independently.

Is a temperature of 100.4 °F really an emergency during neutropenia?

Yes. Guidelines treat a temperature of 38.0 °C (100.4 °F) sustained for an hour, or a single reading of 38.3 °C, as febrile neutropenia requiring urgent assessment, and many teams ask you to call at the lower figure without waiting. Without neutrophils, infection can spread within hours and the usual signs may be absent. Do not take fever-reducing medicine to see whether it settles before calling.

Why did my team wait a few days after my growth factor injection before drawing blood?

Growth factor medicines push the marrow to release neutrophils quickly, including many immature forms, so a count drawn while the medicine is active can read higher than the marrow would manage on its own. Waiting a few days lets the team see the marrow’s unassisted output, which is a better guide to whether it has genuinely recovered and whether the next cycle can proceed as planned.

Do I need to follow a neutropenic diet while my count recovers?

Randomized trials have not shown that a strict neutropenic diet, which avoids raw fruit and vegetables, prevents more infections than standard food safety: washing produce, cooking meat, eggs and fish thoroughly, and avoiding unpasteurized products. Many centers have relaxed the old rules for this reason. Follow your own team’s current advice, which reflects their assessment of your risk and may differ from what others were told years ago.

Once my neutrophils are back to normal, is my immune system fully recovered?

Not necessarily. Neutrophils are the fastest white cells to recover, but lymphocytes and antibody responses can lag for weeks or months after intensive treatment or transplantation. This is why some precautions, and decisions about vaccination timing, are handled separately from the neutrophil count. Your team will tell you when the broader immune recovery is considered adequate for each activity.

References

• Cleveland Clinic: Neutropenia
• MedlinePlus: Blood Differential Test
• NHS: Chemotherapy side effects

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.